MENU
+Compare
CELU
Stock ticker: NASDAQ
AS OF
Jan 23, 04:59 PM (EDT)
Price
$2.33
Change
+$0.01 (+0.43%)
Capitalization
51.71M

CELU Celularity Forecast, Technical & Fundamental Analysis

a blank check company, which focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization

Industry Biotechnology
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CELU with price predictions
Jan 08, 2025

CELU in upward trend: price may jump up because it broke its lower Bollinger Band on December 30, 2024

CELU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 41 cases where CELU's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where CELU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CELU just turned positive on January 03, 2025. Looking at past instances where CELU's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CELU advanced for three days, in of 224 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CELU as a result. In of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELU declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.993) is normal, around the industry mean (15.198). P/E Ratio (0.000) is within average values for comparable stocks, (88.809). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.840). CELU has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.243) is also within normal values, averaging (264.909).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CELU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CELU is expected to report earnings to fall 99.27% to -2 cents per share on August 14

Celularity CELU Stock Earnings Reports
Q2'23
Est.
$-0.03
Q1'23
Missed
by $3.86
Q4'22
Beat
by $1.75
Q3'22
Beat
by $0.56
Q2'22
Beat
by $3.46
The last earnings report on May 15 showed earnings per share of -409 cents, missing the estimate of -23 cents. With 60.61K shares outstanding, the current market capitalization sits at 51.71M.
A.I. Advisor
published General Information

General Information

a blank check company, which focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
170 Park Avenue
Phone
+1 908 768-2170
Employees
225
Web
https://www.celularity.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VRDN18.760.41
+2.23%
Viridian Therapeutics
CSX33.670.43
+1.29%
CSX Corp
GGB2.930.02
+0.69%
Gerdau SA
SOHU12.810.01
+0.12%
Sohu.com Limited
OTLK2.04-0.05
-2.39%
Outlook Therapeutics

CELU and Stocks

Correlation & Price change

A.I.dvisor tells us that CELU and NVCT have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELU and NVCT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELU
1D Price
Change %
CELU100%
-0.86%
NVCT - CELU
28%
Poorly correlated
+5.25%
FATE - CELU
27%
Poorly correlated
N/A
PRAX - CELU
27%
Poorly correlated
-2.50%
RNAC - CELU
26%
Poorly correlated
+1.89%
SAGE - CELU
26%
Poorly correlated
+0.14%
More